"Pyrimidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.
| Descriptor ID |
D011744
|
| MeSH Number(s) |
D03.383.742.698
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidinones".
This graph shows the total number of publications written about "Pyrimidinones" by people in this website by year, and whether "Pyrimidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 5 | 0 | 5 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 3 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 6 | 7 |
| 2020 | 3 | 5 | 8 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 3 | 1 | 4 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidinones" by people in Profiles.
-
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Mol Cancer Ther. 2026 May 04; 25(5):844-859.
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 11 07; 391(18):1709-1720.
-
Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for Cryptosporidium. Mol Biochem Parasitol. 2024 12; 260:111637.
-
Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning-Feuerstein-Mims syndrome. Pediatr Dermatol. 2024 May-Jun; 41(3):523-525.
-
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15; 130(10):1784-1796.
-
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 2023 07 15; 129(14):2245-2255.
-
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
-
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. J Clin Oncol. 2021 11 20; 39(33):3705-3715.
-
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther. 2021 07; 20(7):1257-1269.